Prostate Cancer Clinical Trial
Official title:
Medical Ethics Committee of Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University
This trial aims to evaluate the efficacy and safety of neoadjuvant therapy with Darolutamide combined with Androgen-Deprivation Therapy in High-risk/Very high-risk localized prostate cancer. This trial is A prospective, single-arm, multicenter clinical trial. Treatment cycle is 24 weeks,
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 1, 2025 |
Est. primary completion date | January 1, 2023 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Patients must be = 18 and =75 years of age; 2. All patients must have a histologically or cytologically diagnosis of prostate cancer,without distant metastasis, and suitable for radical prostatectomy; 3. All patients meet at least one of the following criteria: 1. multi-parameter MRI or PSMA PET / CT shows clinical staging of primary tumor = T3; 2. Gleason score of primary tumor = 8; 3. prostate specific antigen (PSA) =20 ng/ml; d) Radiographic assessment of regional lymph node metastases (N1); 4. Eastern Cooperative Oncology Group (ECOG) physical condition score 0- 1; 5. Patients must have adequate organ function: hematologic function:within 28 days prior to registration as evidenced by: white blood cell (WBC) = 4.0 × 109 / L, platelets= 100 × 109 / L, hemoglobin = 9 g / dL and international normalized ratio (INR) < 1.5; renal function:within 28 days prior to registration, as evidenced by serum creatinine =2×ULN; hepatic function: within 28 days prior to registration, as evidenced by: total bilirubin (TBIL)=1.5 x upper limit of normal (ULN),and SGOT (AST) and SGPT (ALT) = 2.5 x ULN; 6. Patients must participate voluntarily and sign an informed consent form (ICF), indicating that they understand the purpose and required procedures of the study, and are willing to participate in. Patients must be willing to obey the prohibitions and restrictions specified in the research protocol. 7. Patients of childbearing potential must be willing to take high-efficiency contraceptive measures during the study period and within 120 days after the last dose of treatment. Exclusion Criteria: 1. Patients with prostate having neuroendocrine, small cell, or sarcoma-like features are not eligible. 2. Patients with low-risk and medium-risk, localized prostate cancer (the following conditions are met at the same time) are not eligible: multiparameter MRI or PSMA PET / CT shows clinical staging of primary tumor < T3, Gleason score of primary tumor < 8, and prostate specific antigen (PSA)? 3. Patients with clinical or radiological evidence of regional or extra-regional lymph node metastases or bone metastases or visceral metastases are not eligible.(any M1)? 4. Patients who have previously received androgen deprivation therapy (medical or surgical) more than 3 months or focal treatment of prostate cancer or prostate cancer radiotherapy or prostate cancer chemotherapy are not eligible 5. Patients with severe or uncontrolled concurrent infections are not eligible? 6. Patients must not have New York Heart Association Class III or IV congestive heart failure at the time of screening. Patients must not have any thromboembolic event, unstable angina pectoris, myocardial infarction within 6 months prior to registration. 7. Patients must not have uncontrolled severe hypertension, persistent uncontrolled diabetes, oxygen-dependent lung disease, chronic liver disease, or HIV infection. 8. Patients must not have had other malignancies other than prostate cancer in the past 5 years, but cured basal cell or squamous cell skin cancers can be enrolled. 9. The patient is mentally ill, mentally disabled or incapable of giving informed consent |
Country | Name | City | State |
---|---|---|---|
China | Hongqian Guo | Nanning | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | First Affiliated Hospital of Zhejiang University, The First Affiliated Hospital of Soochow University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change From Baseline in Quality of Life as assessed by FACT-P | Defined by Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire | up to 2 years | |
Other | Change From Baseline in Quality of life as assessed by BPI-SF | Defined by worst pain item based on BPI-SF questionnaire. | up to 2 years | |
Other | Change From Baseline in Quality of life as assessed by EPIC-26 | Defined by EPIC-26 questionnaire. | up to 2 years | |
Primary | Pathological Response Rate (pCR or MRD) | Pathological Response Rate is defined as the pCR(Pathologic Complete Response Rate) or MRD (Proportion of Subjects With Minimal Residual Disease) Pathologic Complete Response Rate is defined as the proportion of subjects with no morphologically recognizable cancer cell in tumor specimens after radical prostatectomy. Proportion of Subjects With Minimal Residual Disease is defined as the proportion of subjects that have residual tumors with maximum diameter of 5 mm or less after radical prostatectomy or residual cancer burden <0.25cm3. |
up to 8months | |
Secondary | AEs/SAEs | The level of AEs defined by NCI-CTCAE v5.0. Safety assessments will be assessed and documented after initiation of study drug, regardless of relationship to study drug. The level of complications defined by Clavien-Dindo classification. |
Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first | |
Secondary | PSA biochemical progression-free survival rate | Defined as the proportion of patients who did not experience biochemical progression or death within 3 years of initiation of darotamide treatment; biochemical progression was defined as an increase in serum PSA level to >0.2 ng/ml with 2 consecutive increases at least 3 months apart | 3 years | |
Secondary | Rate of Positive Surgical Margins | The proportion of subjects with positive surgical margins after radical prostatectomy | up to 8 months | |
Secondary | Rate of Stage Degradation | The proportion of subjects whose tumor clinical or pathological stage degradation after neoadjuvant therapy. | up to 8 months | |
Secondary | PSA response rate | The proportion of subjects with a =98% reduction in nadir PSA from baseline PSA during neoadjuvant therapy | up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |